trial

D-Serine Treatment For Tardive Dyskinesia

NCTId NCT01804920
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 16 (actual)
Sponsored by Herzog Hospital
Primary completion 2019-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
16 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2013-01
Primary completion
2019-01
Eligibility
ALL · 18 Years · 70 Years

Interventions & indications

Drugs
D-serine

Sponsors

Herzog HospitalLead Sponsor

Investigators

1
Uriel Heresco-Levy, MDPrincipal Investigator

Sites

1 total
Jerusalem, Israel

Facts & assertions

4 sourced
Enrollment
16
Phase
NA
Primary Completion Date
2019-01
Status
UNKNOWN
relationships
The graph out of here
drug
D-serine
drug
lead_sponsor
Herzog Hospital
company
indication
Schizophrenia and Schizoaffective Disorder
indication
Psychotic Disorders
indication
Tardive Dyskinesia
indication
investigator
Uriel Heresco-Levy, MD
person